Avalyn Raises $175m To Fund Inhaled Versions Of Pulmonary Fibrosis Drugs

 
• By Joseph Haas
  
Pulmonary disease
Avalyn hopes its inhaled therapies will improve on the profiles of existing IPF drugs • Source: Shutterstock

More from Financing

More from Business